Provided by Tiger Trade Technology Pte. Ltd.

Cogent Biosciences, Inc.

36.73
+1.424.02%
Post-market: 36.33-0.4015-1.09%19:30 EDT
Volume:2.52M
Turnover:92.18M
Market Cap:6.37B
PE:-17.00
High:37.22
Open:35.75
Low:35.40
Close:35.31
52wk High:43.73
52wk Low:11.60
Shares:173.52M
Float Shares:166.83M
Volume Ratio:1.75
T/O Rate:1.51%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-2.1600
EPS(LYR):-2.5504
ROE:-109.74%
ROA:-43.84%
PB:13.63
PE(LYR):-14.40

Loading ...

Cogent Biosciences Q2 Operating Expenses USD 102.638 Million

THOMSON REUTERS
·
Aug 10

Cogent Biosciences - Submits Nda to FDA for Bezuclastinib in Advanced Systemic Mastocytosis

THOMSON REUTERS
·
Jun 30

Cogent Biosciences Submits FDA NDA for Bezuclastinib in Advanced Systemic Mastocytosis

Reuters
·
Jun 30

Why Cogent Biosciences (COGT) Is Up 6.7% After Russell Index Removal Reshapes Its Investor Base

Simply Wall St.
·
Jun 30

H.C. Wainwright Sticks to Its Buy Rating for Cogent Biosciences (COGT)

TIPRANKS
·
Jun 17

Wall Street Analysts Are Bullish on Top Healthcare Picks

TIPRANKS
·
Jun 15

Wedbush Keeps Their Buy Rating on Cogent Biosciences (COGT)

TIPRANKS
·
Jun 15

Cogent Biosciences (COGT) Is Up 6.7% After Positive PEAK Trial Data and FDA Priority Review - What's Changed

Simply Wall St.
·
Jun 13

Cogent Biosciences' Potential Rare Blood Disease Treatment Meets Endpoints in Clinical Trial

MT Newswires Live
·
Jun 12

Cogent Biosciences - Bezuclastinib Continues to Show Favorable Safety and Tolerability Profile

THOMSON REUTERS
·
Jun 12

Cogent Biosciences - to Submit Apex Nda in June 2026

THOMSON REUTERS
·
Jun 12

Cogent Biosciences - Bezuclastinib Shows 65% Orr per Miwg and 81% Orr per Ppr in Advsm Patients

THOMSON REUTERS
·
Jun 12

Cogent Biosciences says mutant-selective JAK2 V617F inhibitor CGT1145 on track for IND in 2026

Reuters
·
Jun 12

Cogent says bezuclastinib posts 65% response rate in APEX trial for advanced systemic mastocytosis

Reuters
·
Jun 12

Cogent Biosciences shareholders elect directors at annual meeting

Reuters
·
Jun 12

Compass Pathways targets late 2027 approval for treatment-resistant depression psychedelic therapy

Reuters
·
Jun 05

Analysts Have Conflicting Sentiments on These Healthcare Companies: Summit Therapeutics (SMMT), Oculis Holding (OCS) and Cogent Biosciences (COGT)

TIPRANKS
·
Jun 01

Analysts Offer Insights on Healthcare Companies: Nuvalent (NUVL), Cogent Biosciences (COGT) and Anteris Technologies Global Corp. (AVR)

TIPRANKS
·
Jun 01

Cogent Biosciences announces data from analysis of PEAK Phase 3 trial

TIPRANKS
·
Jun 01

BRIEF-Cogent Biosciences Announces Detailed Clinical Data From Peak Phase 3 Trial With Bezuclastinib In Combination With Sunitinib

Reuters
·
May 30